Back to NVSEFView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Neovascular Age-elated Macular Degeneration (Wet AMD)
View Full LandscapeDrug Information
Target Indication
Neovascular Age-elated Macular Degeneration (Wet AMD)
Clinical Trial
NCT01535950Last updated: 4/9/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
dovitinibPhase 3
Solid Tumors
MF59-eH1N1_fPhase 3
Influenza
FingolimodPhase 3
Multiple Sclerosis
Glycopyrronium bromidePhase 3
Chronic Obstructive Pulmonary Disease
Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccinePhase 3
Swine-Origin Influenza A H1N1 Virus
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts